Àngels Fabra

6.3k total citations · 1 hit paper
84 papers, 5.3k citations indexed

About

Àngels Fabra is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Àngels Fabra has authored 84 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Molecular Biology, 42 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in Àngels Fabra's work include Cancer Cells and Metastasis (18 papers), Cell Adhesion Molecules Research (12 papers) and Cancer-related Molecular Pathways (9 papers). Àngels Fabra is often cited by papers focused on Cancer Cells and Metastasis (18 papers), Cell Adhesion Molecules Research (12 papers) and Cancer-related Molecular Pathways (9 papers). Àngels Fabra collaborates with scholars based in Spain, United States and Italy. Àngels Fabra's co-authors include Motowo Nakajima, Marı́a José Alonso, Amparo Cano, Kevin A. Janes, Danny R. Welch, David Olmeda, Mireia Jordà, Antònia Vinyals, Àngels Sierra and C Bucana and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Àngels Fabra

81 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chitosan nanoparticles as delivery systems for doxorubicin

2001 588 citations Àngels Fabra, Marı́a José Alonso et al. profile →

Peers

Countries citing papers authored by Àngels Fabra

Since Specialization

Citations

This map shows the geographic impact of Àngels Fabra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Àngels Fabra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Àngels Fabra more than expected).

Fields of papers citing papers by Àngels Fabra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Àngels Fabra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Àngels Fabra. The network helps show where Àngels Fabra may publish in the future.

Co-authorship network of co-authors of Àngels Fabra

This figure shows the co-authorship network connecting the top 25 collaborators of Àngels Fabra. A scholar is included among the top collaborators of Àngels Fabra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Àngels Fabra. Àngels Fabra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Loxl3 Promotes Melanoma Progression and Dissemination Influencing Cell Plasticity and Survival 2022 ·Cancers ·(unknown), (unknown), Alfredo Floristán, (unknown), Sara S. Oltra, Antònia Vinyals, Gema Moreno‐Bueno, Àngels Fabra, Francisco Portillo, Amparo Cano, Patricia G. Santamarı́a	15
2	AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy 2017 ·Journal of Investigative Dermatology ·Joan Anton Puig‐Butillé, Antònia Vinyals, (unknown), Paula Aguilera, (unknown), Gemma Tell‐Martí, Joaquim Marcoval, Francesca Mateo, Luís Palomero, Célia Bádenas, Josep M. Piulats, Josep Malvehy, Miguel Ángel Pujana, Susana Puig, Àngels Fabra	44
3	Metastatic uveal melanoma 2011 ·Melanoma Research ·Francesc Pons, Nieves Plana, J. Maria Caminal Mitjana, J. Pera, Isabel Fernandes, (unknown), Xavier García del Muro, Joaquim Marcoval, R.M. Penín, Àngels Fabra, Josep M. Piulats	38
4	Role of CXCR4/SDF-1α in the migratory phenotype of hepatoma cells that have undergone epithelial–mesenchymal transition in response to the transforming growth factor-β 2009 ·Cellular Signalling ·Esther Bertrán, Laia Caja, Estanis Navarro, Patricia Sancho, Jèssica Mainez, Miguel Murillo, Antònia Vinyals, Àngels Fabra, Isabel Fabregat	62
5	SNAI1 Is Required for Tumor Growth and Lymph Node Metastasis of Human Breast Carcinoma MDA-MB-231 Cells 2007 ·Cancer Research ·David Olmeda, Gema Moreno‐Bueno, Juana M. Flores, Àngels Fabra, Francisco Portillo, Amparo Cano	186
6	Changes in the invasive and metastatic capacities of HT‐29/M3 cells induced by the expression of fucosyltransferase 1 2007 ·Cancer Science ·Raquel Mejías‐Luque, Anna López‐Ferrer, Marta Garrido, Àngels Fabra, Carme de Bolós	28
7	Genetic Profiling of Epithelial Cells Expressing E-Cadherin Repressors Reveals a Distinct Role for Snail, Slug, and E47 Factors in Epithelial-Mesenchymal Transition 2006 ·Cancer Research ·Gema Moreno‐Bueno, Eva Cubillo, David Sarrió, Héctor Peinado, Socorro Marıá Rodríguez-Pinilla, (unknown), Victoria Bolós, Mireia Jordà, Àngels Fabra, Francisco Portillo, José Palacios, Amparo Cano	261
8	Snail silencing effectively suppresses tumour growth and invasiveness 2006 ·Oncogene ·David Olmeda, Mireia Jordà, Héctor Peinado, Àngels Fabra, Amparo Cano	217
9	V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis 2006 ·Laboratory Investigation ·Laia Miquel‐Serra, Montserrat Serra, Daniel Pérez-Hernández, (unknown), María José Docampo, Rosa M. Rabanal, Inés de Torres, Thomas N. Wight, Àngels Fabra, Anna Bassols	51
10	Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha 2003 ·European Journal of Pharmaceutical Sciences ·Alejandro Sánchez, María Teresa Braña Tobío, (unknown), Àngels Fabra, Marı́a José Alonso	132
11	Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer 2000 ·European Journal of Cancer ·Xavier García del Muro, A. Torregrosa, Juan José Múñoz, Xavier Castellsagué, Enric Condom, Francesc Vigués, Ana Arance, Àngels Fabra, Josep R. Germà	91
12	Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein 1999 ·Gene Therapy ·Antònia Vinyals, Miguel A. Peinado, (unknown), Mariano Monzó, R. Daniel Bonfil, Àngels Fabra	26
13	1H MRS markers of tumour growth in intrasplenic tumours and liver metastasis induced by injection of HT-29 cells in nude mice spleen 1998 ·NMR in Biomedicine ·Ángel Moreno, Lluís López-Barcons, Àngels Fabra, Carles Arús	36
14	Transforming Growth Factor β1Induces Squamous Carcinoma Cell Variants with Increased Metastatic Abilities and a Disorganized Cytoskeleton 1998 ·Experimental Cell Research ·Pilar Frontelo, (unknown), Senén Vilaró, Carlos Gamallo, Àngels Fabra, Miguel Quintanilla	27
15	Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers. 1997 ·PubMed ·(unknown), B. Lloveras, António Figueras, A. Escobedo, Josep Ramón, Àngels Sierra, Àngels Fabra	43
16	Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase 1997 ·Journal of Cutaneous Pathology ·Joaquim Marcoval, Abelardo Moreno, Jordi Graells, August Vidal, Josep M. Escribà, Marta García‐Ramírez, Àngels Fabra	90
17	Apoptosis loss and bcl-2 expression: key determinants of lymph node metastases in T1 breast cancer. 1996 ·PubMed ·Àngels Sierra, Xavier Castellsagué, Silvia Tórtola, A. Escobedo, B. Lloveras, Miguel A. Peinado, Alejandro Marcel Hasslocher‐Moreno, Àngels Fabra	29
18	High frequency of altered HLA class I phenotypes in invasive breast carcinomas 1996 ·Human Immunology ·Teresa Cabrera, María Angustias Parejo Fernández, Àngels Sierra, António Garrido, Alfonso Herruzo, Agustín Escobedo, Àngels Fabra, Federico Garrido	107
19	Suppression of the metastatic phenotype of a mouse skin carcinoma cell line independent of E-cadherin expression and correlated with reduced levels of Ha-ras oncogene products 1996 ·Molecular Carcinogenesis ·Carlos Caulı́n, Lluís López-Barcons, (unknown), Pilar Navarro, Encarnación Lozano, Isabel Rodrigo, Carlos Gamallo, Amparo Cano, Àngels Fabra, Miguel Quintanilla	6
20	Regulation of Gelatinase Production in Metastatic Renal Cell Carcinoma by Organ‐specific Fibroblasts 1994 ·Japanese Journal of Cancer Research ·Kazuo Gohji, Motowo Nakajima, Àngels Fabra, C Bucana, Andrew C. von Eschenbach, Takashi Tsuruo, Isaiah J. Fidler	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact